• 1
    Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 151928.
  • 2
    IARC. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens: personal habits and indoor combustions, vol. 100E. Lyon: International Agency for Research on Cancer, 2012.
  • 3
    Phillips DH. Biomarkers of human exposure to environmental tobacco smoke (ETS). In: Knudsen LE, Merlo DF, eds. Biomarkers and human biomonitoring, vol. 2. Cambridge: Royal Society of Chemistry, 2012. 2349.
  • 4
    IARC. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Tobacco smoke and involuntary smoking, vol. 83. Lyon: International Agency for Research on Cancer, 2004.
  • 5
    Richter E, Branner B. Biomonitoring of exposure to aromatic amines: haemoglobin adducts in humans. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 778: 4962.
  • 6
    Godschalk RW, van Schooten FJ, Bartsch H. A critical evaluation of DNA adducts as biological markers for human exposure to polycyclic aromatic compounds. J Biochem Mol Biol 2003; 36: 111.
  • 7
    Phillips DH. DNA adducts as markers of exposure and risk. Mutat Res 2005; 577: 28492.
  • 8
    Rundle A. Carcinogen-DNA adducts as a biomarker for cancer risk. Mutat Res 2006; 600: 2336.
  • 9
    Gyorffy E, Anna L, Kovacs K, et al. Correlation between biomarkers of human exposure to genotoxins with focus on carcinogen-DNA adducts. Mutagenesis 2008; 23: 118.
  • 10
    Wiencke JK. DNA adduct burden and tobacco carcinogenesis. Oncogene 2002; 21: 737691.
  • 11
    Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 2002; 23: 19792004.
  • 12
    Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002; 3: 4619.
  • 13
    Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002; 23: 90722.
  • 14
    Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 73344.
  • 15
    DeMarini DM. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat Res 2004; 567: 44774.
  • 16
    Proia NK, Paszkiewicz GM, Nasca MA, et al. Smoking and smokeless tobacco-associated human buccal cell mutations and their association with oral cancer—a review. Cancer Epidemiol Biomarkers Prev 2006; 15: 106177.
  • 17
    Godschalk RW, Kleinjans JC. Characterization of the exposure-disease continuum in neonates of mothers exposed to carcinogens during pregnancy. Basic Clin Pharmacol Toxicol 2008; 102: 10917.
  • 18
    Hecht SS. Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol 2008; 21: 16071.
  • 19
    Hatsukami DK, Benowitz NL, Rennard SI, et al. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 2006; 8: 16991.
  • 20
    Hecht SS, Yuan JM, Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol 2010; 23: 10018.
  • 21
    Phillips DH. The formation of DNA adducts. In: Allison MR, ed. The Cancer Handbook, 2nd edn., vol. 1. Chichester: Wiley, 2007. 33850.
  • 22
    Phillips DH, Arlt VM. The 32P-postlabeling assay for DNA adducts. Nat Protoc 2007; 2: 277281.
  • 23
    Alexandrov K, Rojas M, Geneste O, et al. An improved fluorimetric assay for dosimetry of benzo[a]pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 1992; 52: 624853.
  • 24
    Beland FA, Churchwell MI, von Tungeln LS, et al. High-performance liquid chromatography electrospray ionization tandem mass spectrometry for the detection and quantitation of benzo[a]pyrene-DNA adducts. Chem Res Toxicol 2005; 18: 130615.
  • 25
    Poirier MC. Antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA: applications for detection of xenobiotics in biological samples. Mutat Res 1993; 288: 318.
  • 26
    Santella RM. Immunological methods for detection of carcinogen-DNA damage in humans. Cancer Epidemiol Biomarkers Prev 1999; 8: 7339.
  • 27
    Doerge DR, Churchwell MI, Marques MM, et al. Quantitative analysis of 4-aminobiphenyl-C8-deoxyguanosyl DNA adducts produced in vitro and in vivo using HPLC-ES-MS. Carcinogenesis 1999; 20: 105561.
  • 28
    Ricicki EM, Soglia JR, Teitel C, et al. Detection and quantification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl adducts in human pancreas tissue using capillary liquid chromatography-microelectrospray mass spectrometry. Chem Res Toxicol 2005; 18: 6929.
  • 29
    Randall KL, Argoti D, Paonessa JD, et al. An improved liquid chromatography-tandem mass spectrometry method for the quantification of 4-aminobiphenyl DNA adducts in urinary bladder cells and tissues. J Chromatogr A 2010; 1217: 413543.
  • 30
    Al-Atrash J, Zhang YJ, Lin D, et al. Quantitative immunohistochemical analysis of 4-aminobiphenyl-DNA in cultured cells and mice: comparison to gas chromatography/mass spectroscopy analysis. Chem Res Toxicol 1995; 8: 74752.
  • 31
    Singh R, Kaur B, Kalina I, et al. Effects of environmental air pollution on endogenous oxidative DNA damage in humans. Mutat Res 2007; 620: 7182.
  • 32
    Godschalk R, Nair J, van Schooten FJ, et al. Comparison of multiple DNA adduct types in tumor adjacent human lung tissue: effect of cigarette smoking. Carcinogenesis 2002; 23: 20816.
  • 33
    Munnia A, Amasio ME, Peluso M. Exocyclic malondialdehyde and aromatic DNA adducts in larynx tissues. Free Radic Biol Med 2004; 37: 8508.
  • 34
    Munnia A, Bonassi S, Verna A, et al. Bronchial malondialdehyde DNA adducts, tobacco smoking, and lung cancer. Free Radic Biol Med 2006; 41: 1499505.
  • 35
    Zhang Y, Chen SY, Hsu T, et al. Immunohistochemical detection of malondialdehyde-DNA adducts in human oral mucosa cells. Carcinogenesis 2002; 23: 20711.
  • 36
    Wang M, Cheng G, Balbo S, et al. Clear differences in levels of a formaldehyde-DNA adduct in leukocytes of smokers and nonsmokers. Cancer Res 2009; 69: 71704.
  • 37
    Chen L, Wang M, Villalta PW, et al. Quantitation of an acetaldehyde adduct in human leukocyte DNA and the effect of smoking cessation. Chem Res Toxicol 2007; 20: 10813.
  • 38
    Nath RG, Ocando JE, Guttenplan JB, et al. 1,N2-propanodeoxyguanosine adducts: potential new biomarkers of smoking-induced DNA damage in human oral tissue. Cancer Res 1998; 58: 5814.
  • 39
    Zhang S, Villalta PW, Wang M, et al. Detection and quantitation of acrolein-derived 1,N2-propanodeoxyguanosine adducts in human lung by liquid chromatography-electrospray ionization-tandem mass spectrometry. Chem Res Toxicol 2007; 20: 56571.
  • 40
    Godschalk R, Nair J, Kliem HC, et al. Modified immunoenriched (32)P-HPLC assay for the detection of O(4)-ethylthymidine in human biomonitoring studies. Chem Res Toxicol 2002; 15: 4337.
  • 41
    Balbo S, Villalta PW, Hecht SS. Quantitation of 7-ethylguanine in leukocyte DNA from smokers and nonsmokers by liquid chromatography-nanoelectrospray-high resolution tandem mass spectrometry. Chem Res Toxicol 2011; 24: 172934.
  • 42
    Foiles PG, Akerkar SA, Carmella SG, et al. Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. Chem Res Toxicol 1991; 4: 3648.
  • 43
    Scherer G, Engl J, Urban M, et al. Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol 2007; 47: 17183.
  • 44
    Schettgen T, Muller J, Fromme H, et al. Simultaneous quantification of haemoglobin adducts of ethylene oxide, propylene oxide, acrylonitrile, acrylamide and glycidamide in human blood by isotope-dilution GC/NCI-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 246773.
  • 45
    von Stedingk H, Vikstrom AC, Rydberg P, et al. Analysis of hemoglobin adducts from acrylamide, glycidamide, and ethylene oxide in paired mother/cord blood samples from Denmark. Chem Res Toxicol 2011; 24: 195765.
  • 46
    Bryant MS, Skipper PL, Tannenbaum SR, et al. Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers. Cancer Res 1987; 47: 6028.
  • 47
    Lee BM, Santella RM. Quantitation of protein adducts as a marker of genotoxic exposure: immunologic detection of benzo[a]pyrene—globin adducts in mice. Carcinogenesis 1988; 9: 17737.
  • 48
    Ragin AD, Crawford KE, Etheredge AA, et al. A gas chromatography-isotope dilution high-resolution mass spectrometry method for quantification of isomeric benzo[a]pyrene diol epoxide hemoglobin adducts in humans. J Anal Toxicol 2008; 32: 72836.
  • 49
    Lee BM, Yin BY, Herbert R, et al. Immunologic measurement of polycyclic aromatic hydrocarbon-albumin adducts in foundry workers and roofers. Scand J Work Environ Health 1991; 17: 1904.
  • 50
    Chung MK, Riby J, Li H, et al. A sandwich enzyme-linked immunosorbent assay for adducts of polycyclic aromatic hydrocarbons with human serum albumin. Anal Biochem 2010; 400: 1239.
  • 51
    Islam GA, Greibrokk T, Harvey RG, et al. HPLC analysis of benzo[a]pyrene-albumin adducts in benzo[a]pyrene exposed rats. Detection of cis-tetrols arising from hydrolysis of adducts of anti- and syn-BPDE-III with proteins. Chem Biol Interact 1999; 123: 13348.
  • 52
    Myers SR, Ali MY. Haemoglobin adducts as biomarkers of exposure to tobacco-related nitrosamines. Biomarkers 2008; 13: 14559.
  • 53
    Ghosh A, Choudhury A, Das A, et al. Cigarette smoke induces p-benzoquinone-albumin adduct in blood serum: implications on structure and ligand binding properties. Toxicology 2012; 292: 7889.
  • 54
    Arif JM, Dresler C, Clapper ML, et al. Lung DNA adducts detected in human smokers are unrelated to typical polyaromatic carcinogens. Chem Res Toxicol 2006; 19: 2959.
  • 55
    Pratt MM, John K, MacLean AB, et al. Polycyclic aromatic hydrocarbon (PAH) exposure and DNA adduct semi-quantitation in archived human tissues. Int J Environ Res Public Health 2011; 8: 267591.
  • 56
    Weston A. Physical methods for the detection of carcinogen-DNA adducts in humans. Mutat Res 1993; 288: 1929.
  • 57
    Singh R, Farmer PB. Liquid chromatography-electrospray ionization-mass spectrometry: the future of DNA adduct detection. Carcinogenesis 2006; 27: 17896.
  • 58
    Li H, Grigoryan H, Funk WE, et al. Profiling Cys34 adducts of human serum albumin by fixed-step selected reaction monitoring. Mol Cell Proteomics: MCP 2011; 10: M110.004606.
  • 59
    IARC. IARC monographs on the evaluation of carcinogenic risks to humans.Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures, vol. 92. Lyon, International Agency for Research on Cancer, 2010.
  • 60
    Benhamou S, Laplanche A, Guillonneau B, et al. DNA adducts in normal bladder tissue and bladder cancer risk. Mutagenesis 2003; 18: 4458.
  • 61
    Phillips DH, Hewer A, Scholefield JH, et al. Smoking-related DNA adducts in anal epithelium. Mutat Res 2004; 560: 16772.
  • 62
    Chen SY, Wang LY, Lunn RM, et al. Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls. Int J Cancer 2002; 99: 1421.
  • 63
    Schwartz JL, Muscat JE, Baker V, et al. Oral cytology assessment by flow cytometry of DNA adducts, aneuploidy, proliferation and apoptosis shows differences between smokers and non-smokers. Oral Oncol 2003; 39: 84254.
  • 64
    Pratt MM, Sirajuddin P, Poirier MC, et al. Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study. Mutat Res 2007; 624: 11423.
  • 65
    Pratt MM, King LC, Adams LD, et al. Assessment of multiple types of DNA damage in human placentas from smoking and nonsmoking women in the Czech Republic. Environ Mol Mutagen 2011; 52: 5868.
  • 66
    Rojas M, Marie B, Vignaud JM, et al. High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma. Cancer Lett 2004; 207: 15763.
  • 67
    Varkonyi A, Kelsey K, Semey K, et al. Polyphenol associated-DNA adducts in lung and blood mononuclear cells from lung cancer patients. Cancer Lett 2006; 236: 2431.
  • 68
    Gyorffy E, Anna L, Gyori Z, et al. DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: correlations between tissues and detection by 32P-postlabelling and immunoassay. Carcinogenesis 2004; 25: 12019.
  • 69
    Binkova B, Chvatalova I, Lnenickova Z, et al. PAH-DNA adducts in environmentally exposed population in relation to metabolic and DNA repair gene polymorphisms. Mutat Res 2007; 620: 4961.
  • 70
    Knudsen LE, Gaskell M, Martin EA, et al. Genotoxic damage in mine workers exposed to diesel exhaust, and the effects of glutathione transferase genotypes. Mutat Res 2005; 583: 12032.
  • 71
    Shantakumar S, Gammon MD, Eng SM, et al. Residential environmental exposures and other characteristics associated with detectable PAH-DNA adducts in peripheral mononuclear cells in a population-based sample of adult females. J Expo Anal Environ Epidemiol 2005; 15: 48290.
  • 72
    Bak H, Autrup H, Thomsen BL, et al. Bulky DNA adducts as risk indicator of lung cancer in a Danish case-cohort study. Int J Cancer 2006; 118: 161822.
  • 73
    Pavanello S, Pulliero A, Saia BO, et al. Determinants of anti-benzo[a]pyrene diol epoxide-DNA adduct formation in lymphomonocytes of the general population. Mutat Res 2006; 611: 5463.
  • 74
    van Leeuwen DM, van Agen E, Gottschalk RW, et al. Cigarette smoke-induced differential gene expression in blood cells from monozygotic twin pairs. Carcinogenesis 2007; 28: 6917.
  • 75
    Taioli E, Sram RJ, Binkova B, et al. Biomarkers of exposure to carcinogenic PAHs and their relationship with environmental factors. Mutat Res 2007; 620: 1621.
  • 76
    Peluso M, Srivatanakul P, Munnia A, et al. DNA adduct formation among workers in a Thai industrial estate and nearby residents. Sci Total Environ 2008; 389: 2838.
  • 77
    Eriksen KT, Sorensen M, Autrup H, et al. Lifestyle, environmental, and genetic predictors of bulky DNA adducts in a study population nested within a prospective Danish cohort. J Toxicol Environ Health A 2010; 73: 58395.
  • 78
    Funck-Brentano C, Raphael M, Lafontaine M, et al. Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. Lung Cancer 2006; 54: 118.
  • 79
    Veglia F, Matullo G, Vineis P. Bulky DNA adducts and risk of cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 15760.
  • 80
    Veglia F, Loft S, Matullo G, et al. DNA adducts and cancer risk in prospective studies: a pooled analysis and a meta-analysis. Carcinogenesis 2008; 29: 9326.
  • 81
    Ricceri F, Godschalk RW, Peluso M, et al. Bulky DNA adducts in white blood cells: a pooled analysis of 3,600 subjects. Cancer Epidemiol Biomarkers Prev 2010; 19: 317481.
  • 82
    Gammon MD, Santella RM, Neugut AI, et al. Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev 2002; 11: 67785.
  • 83
    Gammon MD, Sagiv SK, Eng SM, et al. Polycyclic aromatic hydrocarbon-DNA adducts and breast cancer: a pooled analysis. Archiv Environ Health 2004; 59: 6409.
  • 84
    Horak S, Polanska J, Widlak P. Bulky DNA adducts in human sperm: relationship with fertility, semen quality, smoking, and environmental factors. Mutat Res 2003; 537: 5365.
  • 85
    Gaspari L, Chang SS, Santella RM, et al. Polycyclic aromatic hydrocarbon-DNA adducts in human sperm as a marker of DNA damage and infertility. Mutat Res 2003; 535: 15560.
  • 86
    Perrin J, Tassistro V, Mandon M, et al. Tobacco consumption and benzo(a)pyrene-diol-epoxide-DNA adducts in spermatozoa: in smokers, swim-up procedure selects spermatozoa with decreased DNA damage. Fertil Steril 2011; 95: 20137.
  • 87
    Faraglia B, Chen SY, Gammon MD, et al. Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. Carcinogenesis 2003; 24: 71925.
  • 88
    Airoldi L, Orsi F, Magagnotti C, et al. Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies. Carcinogenesis 2002; 23: 8616.
  • 89
    Gu D, Turesky RJ, Tao Y, et al. DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 4-aminobiphenyl are infrequently detected in human mammary tissue by liquid chromatography/tandem mass spectrometry. Carcinogenesis 2012; 33: 12430.
  • 90
    Bessette EE, Spivack SD, Goodenough AK, et al. Identification of carcinogen DNA adducts in human saliva by linear quadrupole ion trap/multistage tandem mass spectrometry. Chem Res Toxicol 2010; 23: 123444.
  • 91
    Bessette EE, Goodenough AK, Langouet S, et al. Screening for DNA adducts by data-dependent constant neutral loss-triple stage mass spectrometry with a linear quadrupole ion trap mass spectrometer. Anal Chem 2009; 81: 80919.
  • 92
    Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol Nutr Food Res 2008; 52: 725.
  • 93
    IARC. IARC monographs on the evaluation of carcinogenic risks to humans.Dry cleaning, some chlorinated solvents and other industrial chemicals, vol. 63. Lyon: International Agency for Research on Cancer 1995.
  • 94
    Chen HJ. Analysis of DNA adducts in human samples: acrolein-derived exocyclic DNA adducts as an example. Mol Nutr Food Res 2011; 55: 1391400.
  • 95
    Feng Z, Hu W, Hu Y, et al. Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci USA 2006; 103: 154049.
  • 96
    Zhang S, Balbo S, Wang M, et al. Analysis of acrolein-derived 1,N2-propanodeoxyguanosine adducts in human leukocyte DNA from smokers and nonsmokers. Chem Res Toxicol 2011; 24: 11924.
  • 97
    Garcia CC, Angeli JP, Freitas FP, et al. [13C2]-Acetaldehyde promotes unequivocal formation of 1,N2-propano-2′-deoxyguanosine in human cells. J Am Chem Soc 2011; 133: 91403.
  • 98
    Singh R, Kaur B, Farmer PB. Detection of DNA damage derived from a direct acting ethylating agent present in cigarette smoke by use of liquid chromatography-tandem mass spectrometry. Chem Res Toxicol 2005; 18: 24956.
  • 99
    Anna L, Kovacs K, Gyorffy E, et al. Smoking-related O4-ethylthymidine formation in human lung tissue and comparisons with bulky DNA adducts. Mutagenesis 2011; 26: 5237.
  • 100
    Holzle D, Schlobe D, Tricker AR, et al. Mass spectrometric analysis of 4-hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts in human lung. Toxicology 2007; 232: 27785.
  • 101
    Schlobe D, Holzle D, Hatz D, et al. 4-Hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts in lung, lower esophagus and cardia of sudden death victims. Toxicology 2008; 245: 15461.
  • 102
    Heppel CW, Heling AK, Richter E. Ultrasensitive method for the determination of 4-hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts by gas chromatography-high resolution mass spectrometry in mucosal biopsies of the lower esophagus. Anal Bioanal Chem 2009; 393: 152530.
  • 103
    Prokopczyk B, Leder G, Trushin N, et al. 4-Hydroxy-1-(3-pyridyl)-1-butanone, an indicator for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA damage, is not detected in human pancreatic tissue. Cancer Epidemiol Biomarkers Prev 2005; 14: 5401.
  • 104
    NTP, National Toxicology Program. Final report on carcinogens background document for formaldehyde, Rep. Carcinog. Backgr. Doc. (10-5981): i-512, 2010.
  • 105
    Counts ME, Hsu FS, Laffoon SW, et al. Mainstream smoke constituent yields and predicting relationships from a worldwide market sample of cigarette brands: ISO smoking conditions. Regul Toxicol Pharmacol 2004; 39: 11134.
  • 106
    IARC. IARC monographs on the evaluation of carcinogenic risks to humans.Formaldehyde, 2-butoxyethanol and 1-tert-butoxypropan-2-ol, vol. 88. Lyon: International Agency for Research on Cancer, 2006.
  • 107
    Speed N, Blair IA. Cyclooxygenase- and lipoxygenase-mediated DNA damage. Cancer Metastasis Rev 2011; 30: 43747.
  • 108
    Winczura A, Zdzalik D, Tudek B. Damage of DNA and proteins by major lipid peroxidation products in genome stability. Free Radic Res 2012; 46: 44259.
  • 109
    Peluso M, Srivatanakul P, Munnia A, et al. Malondialdehyde-deoxyguanosine adducts among workers of a Thai industrial estate and nearby residents. Environ Health Perspect 2010; 118: 559.
  • 110
    Bono R, Romanazzi V, Munnia A, et al. Malondialdehyde-deoxyguanosine adduct formation in workers of pathology wards: the role of air formaldehyde exposure. Chem Res Toxicol 2010; 23: 13428.
  • 111
    Peluso M, Munnia A, Risso GG, et al. Breast fine-needle aspiration malondialdehyde deoxyguanosine adduct in breast cancer. Free Radic Res 2011; 45: 47782.
  • 112
    Sarkar M, Stabbert R, Kinser RD, et al. CYP1A2 and NAT2 phenotyping and 3-aminobiphenyl and 4-aminobiphenyl hemoglobin adduct levels in smokers and non-smokers. Toxicol Appl Pharmacol 2006; 213: 198206.
  • 113
    Roethig HJ, Munjal S, Feng S, et al. Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob Res 2009; 11: 121625.
  • 114
    Seyler TH, Reyes LR, Bernert JT. Analysis of 4-aminobiphenyl hemoglobin adducts in smokers and nonsmokers by pseudo capillary on-column gas chromatography- tandem mass spectrometry. J Anal Toxicol 2010; 34: 30411.
  • 115
    Dallinga JW, Haenen GR, Bast A, et al. The effect of the trolox equivalent antioxidant capacity (TEAC) in plasma on the formation of 4-aminobiphenylhaemoglobin adducts in smokers. Biomarkers 2002; 7: 2918.
  • 116
    Schettgen T, Weiss T, Drexler H, et al. A first approach to estimate the internal exposure to acrylamide in smoking and non-smoking adults from Germany. Int J Hyg Environ Health 2003; 206: 914.
  • 117
    Schettgen T, Rossbach B, Kutting B, et al. Determination of haemoglobin adducts of acrylamide and glycidamide in smoking and non-smoking persons of the general population. Int J Hyg Environ Health 2004; 207: 5319.
  • 118
    Hagmar L, Wirfalt E, Paulsson B, et al. Differences in hemoglobin adduct levels of acrylamide in the general population with respect to dietary intake, smoking habits and gender. Mutat Res 2005; 580: 15765.
  • 119
    Vesper HW, Bernert JT, Ospina M, et al. Assessment of the relation between biomarkers for smoking and biomarkers for acrylamide exposure in humans. Cancer Epidemiol Biomarkers Prev 2007; 16: 24718.
  • 120
    Vesper HW, Slimani N, Hallmans G, et al. Cross-sectional study on acrylamide hemoglobin adducts in subpopulations from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. J Agric Food Chem 2008; 56: 604653.
  • 121
    Wirfalt E, Paulsson B, Tornqvist M, et al. Associations between estimated acrylamide intakes, and hemoglobin AA adducts in a sample from the Malmo Diet and Cancer cohort. Eur J Clin Nutr 2008; 62: 31423.
  • 122
    Kutting B, Uter W, Drexler H. The association between self-reported acrylamide intake and hemoglobin adducts as biomarkers of exposure. Cancer Causes Control 2008; 19: 27381.
  • 123
    Kutting B, Schettgen T, Schwegler U, et al. Acrylamide as environmental noxious agent: a health risk assessment for the general population based on the internal acrylamide burden. Int J Hyg Environ Health 2009; 212: 47080.
  • 124
    Vesper HW, Caudill SP, Osterloh JD, et al. Exposure of the U.S. population to acrylamide in the National Health and Nutrition Examination Survey 2003–2004. Environ Health Perspect 2010; 118: 27883.
  • 125
    Tran NL, Barraj LM, Murphy MM, et al. Dietary acrylamide exposure and hemoglobin adducts—National Health and Nutrition Examination Survey (2003–04). Food Chem Toxicol 2010; 48: 3098108.
  • 126
    Boettcher MI, Schettgen T, Kutting B, et al. Mercapturic acids of acrylamide and glycidamide as biomarkers of the internal exposure to acrylamide in the general population. Mutat Res 2005; 580: 16776.
  • 127
    Schettgen T, Broding HC, Angerer J, et al. Hemoglobin adducts of ethylene oxide, propylene oxide, acrylonitrile and acrylamide-biomarkers in occupational and environmental medicine. Toxicol Lett 2002; 134: 6570.
  • 128
    Mendes P, Liang Q, Frost-Pineda K, et al. The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US. Regul Toxicol Pharmacol 2009; 55: 1727.
  • 129
    Bernert JT, Jain RB, Pirkle JL, et al. Urinary tobacco-specific nitrosamines and 4-aminobiphenyl hemoglobin adducts measured in smokers of either regular or light cigarettes. Nicotine Tob Res 2005; 7: 72938.
  • 130
    Wang LE, Hu Z, Sturgis EM, et al. Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. Clin Cancer Res 2010; 16: 76474.
  • 131
    Lin J, Kadlubar FF, Spitz MR, et al. A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 18326.
  • 132
    Speina E, Zielinska M, Barbin A, et al. Decreased repair activities of 1,N(6)-ethenoadenine and 3,N(4)-ethenocytosine in lung adenocarcinoma patients. Cancer Res 2003; 63: 43517.
  • 133
    Radak Z, Goto S, Nakamoto H, et al. Lung cancer in smoking patients inversely alters the activity of hOGG1 and hNTH1. Cancer Lett 2005; 219: 1915.
  • 134
    Orlow I, Park BJ, Mujumdar U, et al. DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. J Clin Oncol 2008; 26: 35606.
  • 135
    Feng Z, Hu W, Tang MS. Trans-4-hydroxy-2-nonenal inhibits nucleotide excision repair in human cells: a possible mechanism for lipid peroxidation-induced carcinogenesis. Proc Natl Acad Sci USA 2004; 101: 8598602.
  • 136
    Feng Z, Hu W, Marnett LJ, et al. Malondialdehyde, a major endogenous lipid peroxidation product, sensitizes human cells to UV- and BPDE-induced killing and mutagenesis through inhibition of nucleotide excision repair. Mutat Res 2006; 601: 12536.
  • 137
    Godschalk R, Hogervorst J, Albering H, et al. Interaction between cadmium and aromatic DNA adducts in hprt mutagenesis during foetal development. Mutagenesis 2005; 20: 1815.
  • 138
    Povey AC, O'Donnell P, Barber P, et al. Smoking is associated with a decrease of O6-alkylguanine-DNA alkyltransferase activity in bronchial epithelial cells. Int J Cancer 2006; 119: 4636.
  • 139
    Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21: 743551.
  • 140
    Feng Z, Hu W, Chen JX, et al. Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J Natl Cancer Inst 2002; 94: 152736.
  • 141
    Ziegel R, Shallop A, Jones R, et al. K-ras gene sequence effects on the formation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-DNA adducts. Chem Res Toxicol 2003; 16: 54150.
  • 142
    Kim SI, Pfeifer GP, Besaratinia A. Lack of mutagenicity of acrolein-induced DNA adducts in mouse and human cells. Cancer Res 2007; 67: 116407.
  • 143
    Wang HT, Zhang S, Hu Y, et al. Mutagenicity and sequence specificity of acrolein-DNA adducts. Chem Res Toxicol 2009; 22: 5117.
  • 144
    Matter B, Guza R, Zhao J, et al. Sequence distribution of acetaldehyde-derived N2-ethyl-dG adducts along duplex DNA. Chem Res Toxicol 2007; 20: 137987.
  • 145
    Anna L, Holmila R, Kovacs K, et al. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary. Mutagenesis 2009; 24: 47580.
  • 146
    Mordukhovich I, Rossner P, Jr, Terry MB, et al. Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors. Environ Health Perspect 2010; 118: 5118.
  • 147
    Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463: 18490.
  • 148
    Le Marchand L. The predominance of the environment over genes in cancer causation: implications for genetic epidemiology. Cancer Epidemiol Biomarkers Prev 2005; 14: 10379.
  • 149
    Taioli E. Gene-environment interaction in tobacco-related cancers. Carcinogenesis 2008; 29: 146774.
  • 150
    Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6: 94760.
  • 151
    Firozi PF, Bondy ML, Sahin AA, et al. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis 2002; 23: 3016.
  • 152
    Lodovici M, Luceri C, Guglielmi F, et al. Benzo(a)pyrene diolepoxide (BPDE)-DNA adduct levels in leukocytes of smokers in relation to polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. Cancer Epidemiol Biomarkers Prev 2004; 13: 13428.
  • 153
    Peluso M, Neri M, Margarino G, et al. Comparison of DNA adduct levels in nasal mucosa, lymphocytes and bronchial mucosa of cigarette smokers and interaction with metabolic gene polymorphisms. Carcinogenesis 2004; 25: 245965.
  • 154
    Nock NL, Tang D, Rundle A, et al. Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race. Cancer Epidemiol Biomarkers Prev 2007; 16: 123645.
  • 155
    Hu Y, Li G, Xue X, et al. PAH-DNA adducts in a Chinese population: relationship to PAH exposure, smoking and polymorphisms of metabolic and DNA repair genes. Biomarkers 2008; 13: 2740.
  • 156
    Ketelslegers HB, Gottschalk RW, Godschalk RW, et al. Interindividual variations in DNA adduct levels assessed by analysis of multiple genetic polymorphisms in smokers. Cancer Epidemiol Biomarkers Prev 2006; 15: 6249.
  • 157
    Ketelslegers HB, Godschalk RW, Eskens BJ, et al. Potential role of cytochrome P450–1B1 in the metabolic activation of 4-aminobiphenyl in humans. Mol Carcinog 2009; 48: 68591.
  • 158
    van Schooten FJ, Boots AW, Knaapen AM, et al. Myeloperoxidase (MPO)-463G->A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev 2004; 13: 82833.
  • 159
    Yang M, Coles BF, Delongchamp R, et al. Effects of the ADH3, CYP2E1, and GSTP1 genetic polymorphisms on their expressions in Caucasian lung tissue. Lung Cancer 2002; 38: 1521.
  • 160
    McCarty KM, Santella RM, Steck SE, et al. PAH-DNA adducts, cigarette smoking, GST polymorphisms, and breast cancer risk. Environ Health Perspect 2009; 117: 5528.
  • 161
    Pastorelli R, Cerri A, Mezzetti M, et al. Effect of DNA repair gene polymorphisms on BPDE-DNA adducts in human lymphocytes. Int J Cancer 2002; 100: 913.
  • 162
    Perera FP, Mooney LA, Stampfer M, et al. Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians' Health Cohort Study. Carcinogenesis 2002; 23: 16416.
  • 163
    Piipari R, Nurminen T, Savela K, et al. Glutathione S-transferases and aromatic DNA adducts in smokers' bronchoalveolar macrophages. Lung Cancer 2003; 39: 26572.
  • 164
    Weiserbs KF, Jacobson JS, Begg MD, et al. A cross-sectional study of polycyclic aromatic hydrocarbon-DNA adducts and polymorphism of glutathione S-transferases among heavy smokers by race/ethnicity. Biomarkers 2003; 8: 14255.
  • 165
    Lewis SJ, Cherry NM, Niven RM, et al. Associations between smoking, GST genotypes and N7-methylguanine levels in DNA extracted from bronchial lavage cells. Mutat Res 2004; 559: 118.
  • 166
    Pavanello S, Pulliero A, Clonfero E. Influence of GSTM1 null and low repair XPC PAT+ on anti-B[a]PDE-DNA adduct in mononuclear white blood cells of subjects low exposed to PAHs through smoking and diet. Mutat Res 2008; 638: 195204.
  • 167
    Lin IH, Chao MR, Hu CW, et al. Modification of urinary N7-methylguanine excretion in smokers by glutathione-S-transferase M1 polymorphism. Toxicology 2009; 260: 16.
  • 168
    Alexandrov K, Cascorbi I, Rojas M, et al. CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis 2002; 23: 196977.
  • 169
    Besaratinia A, Kleinjans JC, van Schooten FJ. Biomonitoring of tobacco smoke carcinogenicity by dosimetry of DNA adducts and genotyping and phenotyping of biotransformational enzymes: a review on polycyclic aromatic hydrocarbons. Biomarkers 2002; 7: 20929.
  • 170
    Shen J, Gammon MD, Terry MB, et al. Polymorphisms in XRCC1 modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, dietary antioxidants, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 33642.
  • 171
    Shen J, Gammon MD, Terry MB, et al. Xeroderma pigmentosum complementation group C genotypes/diplotypes play no independent or interaction role with polycyclic aromatic hydrocarbons-DNA adducts for breast cancer risk. Eur J Cancer 2008; 44: 7107.
  • 172
    Hou SM, Falt S, Angelini S, et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 2002; 23: 599603.
  • 173
    Terry MB, Gammon MD, Zhang FF, et al. Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 20538.
  • 174
    Zienolddiny S, Skaug V, Landvik NE, et al. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis 2009; 30: 136871.
  • 175
    Lind H, Zienolddiny S, Ryberg D, et al. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. Lung Cancer 2005; 50: 28590.
  • 176
    Shen J, Beth Terry M, Gammon MD, et al. IGHMBP2 Thr671Ala polymorphism might be a modifier for the effects of cigarette smoking and PAH-DNA adducts to breast cancer risk. Breast Cancer Res Treat 2006; 99: 17.
  • 177
    Crew KD, Gammon MD, Terry MB, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 2007; 28: 254851.
  • 178
    Gaudet MM, Gammon MD, Bensen JT, et al. Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Res Treat 2008; 108: 939.
  • 179
    Hecht SS. Carcinogen derived biomarkers: applications in studies of human exposure to secondhand tobacco smoke. Tob Control 2004; 13 (Suppl 1): i4856.
  • 180
    Hunt CE, Hauck FR. Sudden infant death syndrome. CMAJ 2006; 174: 18619.
  • 181
    Kinney HC, Thach BT. The sudden infant death syndrome. N Engl J Med 2009; 361: 795805.
  • 182
    Rogers JM. Tobacco and pregnancy. Reprod Toxicol 2009; 28: 15260.
  • 183
    Stephan-Blanchard E, Chardon K, Telliez F, et al. Are benzo[a]pyrene-DNA adducts an accurate biomarker of long-term in utero exposure to smoking? Therap Drug Monitor 2011; 33: 32935.
  • 184
    Perera FP, Rauh V, Whyatt RM, et al. Molecular evidence of an interaction between prenatal environmental exposures and birth outcomes in a multiethnic population. Environ Health Perspect 2004; 112: 62630.
  • 185
    Perera FP, Tang D, Tu YH, et al. Biomarkers in maternal and newborn blood indicate heightened fetal susceptibility to procarcinogenic DNA damage. Environ Health Perspect 2004; 112: 11336.
  • 186
    Perera FP, Tang D, Rauh V, et al. Relationships among polycyclic aromatic hydrocarbon-DNA adducts, proximity to the World Trade Center, and effects on fetal growth. Environ Health Perspect 2005; 113: 10627.
  • 187
    Perera FP, Tang D, Rauh V, et al. Relationship between polycyclic aromatic hydrocarbon-DNA adducts, environmental tobacco smoke, and child development in the World Trade Center cohort. Environ Health Perspect 2007; 115: 1497502.
  • 188
    Rossner P, Jr, Milcova A, Libalova H, et al. Biomarkers of exposure to tobacco smoke and environmental pollutants in mothers and their transplacental transfer to the foetus. II. Oxidative damage. Mutat Res 2009; 669: 206.
  • 189
    Topinka J, Milcova A, Libalova H, et al. Biomarkers of exposure to tobacco smoke and environmental pollutants in mothers and their transplacental transfer to the foetus. I. Bulky DNA adducts. Mutat Res 2009; 669: 139.
  • 190
    Sanyal MK, Mercan D, Belanger K, et al. DNA adducts in human placenta exposed to ambient environment and passive cigarette smoke during pregnancy. Birth Defects Res. A, Clin Mol Teratol 2007; 79: 28994.
  • 191
    Wilson SE, Talaska G, Kahn RS, et al. White blood cell DNA adducts in a cohort of asthmatic children exposed to environmental tobacco smoke. Int Archiv Occup Environ Health 2011; 84: 1927.
  • 192
    Besaratinia A, Maas LM, Brouwer EM, et al. A molecular dosimetry approach to assess human exposure to environmental tobacco smoke in pubs. Carcinogenesis 2002; 23: 11716.
  • 193
    Bernert JT, Gordon SM, Jain RB, et al. Increases in tobacco exposure biomarkers measured in non-smokers exposed to sidestream cigarette smoke under controlled conditions. Biomarkers 2009; 14: 8293.
  • 194
    Jiang X, Yuan JM, Skipper PL, et al. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. Cancer Res 2007; 67: 75405.
  • 195
    Bono R, Vincenti M, Schiliro T, et al. Cotinine and N-(2-hydroxyethyl)valine as markers of passive exposure to tobacco smoke in children. J Expo Anal Environ Epidemiol 2005; 15: 6673.
  • 196
    Neri M, Ugolini D, Bonassi S, et al. Children's exposure to environmental pollutants and biomarkers of genetic damage. II. Results of a comprehensive literature search and meta-analysis. Mutat Res 2006; 612: 1439.
  • 197
    Skipper PL, Tannenbaum SR, Ross RK, et al. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 5037.
  • 198
    Myers SR, Ali MY. Determination of tobacco specific hemoglobin adducts in smoking mothers and new born babies by mass spectrometry. Biomarker Insights 2007; 2: 26982.
  • 199
    Kiyohara C, Ohno Y. Sex differences in lung cancer susceptibility: a review. Gender Med 2010; 7: 381401.
  • 200
    Gasperino J. Gender is a risk factor for lung cancer. Med Hypotheses 2011; 76: 32831.
  • 201
    Mollerup S, Berge G, Baera R, et al. Sex differences in risk of lung cancer: expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer 2006; 119: 7414.
  • 202
    Berge G, Mollerup S, S OV, et al. Role of estrogen receptor in regulation of polycyclic aromatic hydrocarbon metabolic activation in lung. Lung Cancer 2004; 45: 28997.
  • 203
    Chen HJ, Kao CF. Effect of gender and cigarette smoking on urinary excretion of etheno DNA adducts in humans measured by isotope dilution gas chromatography/mass spectrometry. Toxicol Lett 2007; 169: 7281.
  • 204
    Collier AC, Dandge SD, Woodrow JE, et al. Differences in DNA-damage in non-smoking men and women exposed to environmental tobacco smoke (ETS). Toxicol Lett 2005; 158: 109.
  • 205
    Airoldi L, Vineis P, Colombi A, et al. 4-Aminobiphenyl-hemoglobin adducts and risk of smoking-related disease in never smokers and former smokers in the European Prospective Investigation into Cancer and Nutrition prospective study. Cancer Epidemiol Biomarkers Prev 2005; 14: 211824.
  • 206
    Mooney LA, Madsen AM, Tang D, et al. Antioxidant vitamin supplementation reduces benzo(a)pyrene-DNA adducts and potential cancer risk in female smokers. Cancer Epidemiol Biomarkers Prev 2005; 14: 23742.
  • 207
    Ramos KS, Moorthy B. Bioactivation of polycyclic aromatic hydrocarbon carcinogens within the vascular wall: implications for human atherogenesis. Drug Metab Rev 2005; 37: 595610.
  • 208
    De Flora S, Izzotti A, Randerath K, et al. DNA adducts and chronic degenerative disease. Pathogenetic relevance and implications in preventive medicine. Mutat Res 1996; 366: 197238.
  • 209
    De Flora S, Izzotti A, Walsh D, et al. Molecular epidemiology of atherosclerosis. Faseb J 1997; 11: 102131.
  • 210
    Binkova B, Smerhovsky Z, Strejc P, et al. DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat Res 2002; 501: 11528.
  • 211
    Nair J, De Flora S, Izzotti A, et al. Lipid peroxidation-derived etheno-DNA adducts in human atherosclerotic lesions. Mutat Res 2007; 621: 95105.
  • 212
    Godschalk RW, Feldker DE, Borm PJ, et al. Body mass index modulates aromatic DNA adduct levels and their persistence in smokers. Cancer Epidemiol Biomarkers Prev 2002; 11: 7903.
  • 213
    Kelley MJ, Glaser EM, Herndon JE, II, et al. Safety and efficacy of weekly oral oltipraz in chronic smokers. Cancer Epidemiol Biomarkers Prev 2005; 14: 8929.
  • 214
    Van Schooten FJ, Besaratinia A, De Flora S, et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol Biomarkers Prev 2002; 11: 16775.
  • 215
    Talaska G, Al-Zoughool M, Malaveille C, et al. Randomized controlled trial: effects of diet on DNA damage in heavy smokers. Mutagenesis 2006; 21: 17983.
  • 216
    Wang MY, Peng L, Lutfiyya MN, et al. Morinda citrifolia (noni) reduces cancer risk in current smokers by decreasing aromatic DNA adducts. Nutr Cancer 2009; 61: 6349.
  • 217
    Schwartz JL, Baker V, Larios E, et al. Molecular and cellular effects of green tea on oral cells of smokers: a pilot study. Mol Nutr Food Res 2005; 49: 4351.
  • 218
    Hakim IA, Chow HH, Harris RB. Green tea consumption is associated with decreased DNA damage among GSTM1-positive smokers regardless of their hOGG1 genotype. J Nutr 2008; 138: 1567S71S.
  • 219
    Ragin C, Minor A, Agudo A, et al. Pooled analysis of studies on DNA adducts and dietary vitamins. Mutat Res 2010; 705: 7782.
  • 220
    Castelao JE, Yuan JM, Gago-Dominguez M, et al. Carotenoids/vitamin C and smoking-related bladder cancer. Int J Cancer 2004; 110: 41723.
  • 221
    Ichiba M, Matsumoto A, Kondoh T, et al. Decreasing urinary PAH metabolites and 7-methylguanine after smoking cessation. Int Archiv Occup Environ Health 2006; 79: 5459.
  • 222
    Roethig HJ, Feng S, Liang Q, et al. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J Clin Pharmacol 2008; 48: 58091.